We have built a highly innovative genome editing platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. We continue to advance our platform and expand our editing capabilities to develop a pipeline of therapies for genetic diseases and share our expertise through strategic partnerships.
We are developing our own pipeline of in vivo gene therapies that will focus on genetic disorders caused by inherited genetic mutations for which no disease-modifying therapies are available.
Our genome editing platform offers a large and diverse collection of novel RGNs and base editors that provide flexible editing and unprecedented access to genomic loci of interest. Our platform is derived from AgBiome’s proprietary collection of tens of thousands of microbes.
Our PlatformTo provide access to genome editing tools and cure disease, we're seeking partnerships with biotech and pharmaceutical companies. Our gene editing systems are available to license non-exclusively for enablement of ex vivo cell therapies as well as exclusively through R&D collaborations for in vivo therapeutic development.
Partner with UsWe are scientists and leaders on a shared mission to make innovative, curative therapies available to patients with devastating genetic diseases.
Our Team
We are a part of ElevateBio’s ecosystem and have access to its proven expertise in cell and gene therapy development, process development and manufacturing capabilities, and other enabling technology platforms, such as induced pluripotent stem cells (iPSCs) and cell, vector, and protein engineering.
ElevateBio